Medical network - August 19 July 2017, 36 people club department released varieties of health-care negotiation as a result, for 22 products, involving a dozen foreign enterprises coverage above 60%, roche number topped with 4 varieties, astrazeneca has three varieties, GSK, bayer, novo nordisk, novartis, Yang Senjun shortlisted for the two varieties. What is the current performance in the global and domestic markets?
Global: most of the negotiation varieties are popular products, and relevant enterprises have high economic strength
Based on popular drug 500 strong database, the PDB in the imported drugs of 22 health talks, statistical global sales of these products in 2016, of which 18 products are a finalist for the 500 strong, roche's three single resistance and drug lenalidomide Clegene are among the top 10, 2016 sales of more than $6.8 billion, far ahead of other products. In addition, there are seven products that are "blockbuster" drugs (annual sales of more than $1 billion).
Chart 1 sales of imported drugs in the world in 2016
Data source: China pharmaceutical industry information center PDB world best-selling drug 500 database
In the above 12 in foreign companies, and other products more or less a finalist for the 2016 global blockbuster drugs to rank, overall, the total number of GSK products (43), most rankings are concentrated in the 101-200 and 351-500 in two stages. The largest number of categories in the 1-100 range were Johnson & Johnson (11), and the performance of Merck, roche and novartis also came close.
FIG. 2 distribution of global TOP500 varieties of imported pharmaceutical companies in 2016
Data source: China pharmaceutical industry information center PDB world best-selling drug 500 database
Domestic: non-exclusive varieties are competitive and exclusive varieties have a game between the rules and regulations
Based on the PDB domestic sample hospital market database, the majority of the 22 healthcare negotiations are exclusive. "Quetiapine flat piece" is more special, there are varieties of production and sales of the three enterprises, and the five specifications of products, in addition to 50 mg not included, 100 mg involves only two state-owned, 300 mg involves first pharmaceutical astrazeneca and suzhou, but the overall market share is very small; 25mg / 200mg is a common competition for the three enterprises, and 25mg is not in the price negotiation scope; Therefore, for 200mg, astrazeneca accounted for 48% of the total in 2016, which will further enhance the market competitiveness of the product/product regulation.
FIG. 3 distribution of market pattern of quintiapine domestic sample hospital in 2016
Data source: China pharmaceutical industry information center PDB domestic sample hospital market database
In addition, although there is no competition from other enterprises, the market layout of multiple products will have some impact. Such as roche rituxan injection, 100 mg/ml and 50 to 500 mg/ml in the price list, and based on its nearly five years of market performance, small size showed a sharp increase in 2016, before the market share of more than has been by far the large size, 500 mg of market in the second half of 2017 is expected to gradually recover, 100 mg of market continues to grow.
Figure 4 market trend of lituximab injection domestic sample hospital (2012-2016, billion yuan)
|
